Hologic Inc
HOLXHologic Inc. (HOLX) is a global healthcare company specializing in medical technology, diagnostic products, and surgical interventions. The company primarily focuses on women's health, offering products for breast health, gynecology, and skeletal health, as well as diagnostic solutions in molecular and reproductive health. Established in 1985, Hologic is known for innovative products that enhance early detection, diagnosis, and treatment of various health conditions.
Company News
The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology i...
The global breast cancer imaging market is expected to grow at a CAGR of 7.7% from 2025 to 2033, driven by rising breast cancer incidence, technological advancements in imaging modalities like tomosynthesis and CESM, and increased government healthcare initiatives for early detection and screening.
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulator...
AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, ...
Law firm Brodsky & Smith has initiated investigations into four major merger transactions, examining whether the boards of Diamond Hill Investment Group, Synchronoss Technologies, Forge Global Holdings, and Hologic breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders.
